<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27438" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Porokeratosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Williams</surname>
            <given-names>Grant M.</given-names>
          </name>
          <aff>Keesler AFB</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dreyer</surname>
            <given-names>Mark A.</given-names>
          </name>
          <aff>Intercoastal Medical Group</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fillman</surname>
            <given-names>Eric P.</given-names>
          </name>
          <aff>San Antonio Military Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Grant Williams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Dreyer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eric Fillman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27438.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Porokeratosis is an uncommon dermatologic disorder that presents with keratotic papules or annular plaques&#x000a0;featuring an elevated border.&#x000a0;The condition&#x000a0;typically occurs on sun-exposed skin, most&#x000a0;often in the fifth decade of life, but can occur at any age and with similar frequencies in males and females. The increased occurrence of disseminated superficial actinic porokeratosis on sun-exposed skin likely indicates that ultraviolet (UV) light is a risk factor.&#x000a0;Although&#x000a0;porokeratosis is usually an acquired disease, there is often a familial predisposition that could signify a hereditary component.&#x000a0;</p>
        <p>This activity&#x000a0;reviews the clinical manifestations of porokeratosis,&#x000a0;including&#x000a0;variants such as disseminated superficial actinic porokeratosis, classical porokeratosis of Mibelli, linear porokeratosis, and other rare types, each exhibiting unique presentations and challenges in diagnosis and management. The session also delves into histologic features, notably the presence of coronoid lamella, aiding in accurate diagnosis through biopsy of the elevated border. The role of&#x000a0;UV light as a risk factor in the development of porokeratosis is discussed, emphasizing the importance of surveillance and management.&#x000a0;Attendees will gain insights into the complexities&#x000a0;of therapeutic interventions, including topical, systemic, and surgical modalities, without&#x000a0;standardized treatment guidelines. With a focus on evaluation, treatment options, and the risk of malignant transformation, this session aims to equip healthcare professionals with a comprehensive understanding of Porokeratosis, facilitating an enhanced team-based approach to patient care and surveillance.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply the comprehensive physical examination techniques necessary to identify and differentiate porokeratosis lesions from other dermatological conditions.</p></list-item><list-item><p>Implement biopsy procedures targeting the characteristic elevated borders to confirm the diagnosis of porokeratosis.</p></list-item><list-item><p>Assess various management approaches for porokeratosis, encompassing topical, systemic, and surgical interventions, and identify individualized treatment plans based on lesion characteristics and patient-specific factors.&#x000a0;</p></list-item><list-item><p>Coordinate care between dermatologists, oncologists, pathologists, and other healthcare providers to apply diverse expertise, facilitating accurate diagnosis, treatment selection, and long-term surveillance of porokeratosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27438&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27438">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27438.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Porokeratosis is an uncommon disorder of keratinization that presents with keratotic papules or annular plaques with an elevated border.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;The&#x000a0;distinct histologic hallmark of porokeratosis is cornoid lamella, a column of tightly fitted parakeratotic cells in the upper epidermis.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref><xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;There are multiple clinical variants of porokeratosis, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Disseminated superficial actinic porokeratosis</p>
          </list-item>
          <list-item>
            <p>Classical porokeratosis of Mibelli</p>
          </list-item>
          <list-item>
            <p>Porokeratosis plantaris, palmaris, et disseminate</p>
          </list-item>
          <list-item>
            <p>Linear porokeratosis&#x000a0;<xref ref-type="bibr" rid="article-27438.r2">[2]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Additionally, rare variants include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Genitogluteal porokeratosis</p>
          </list-item>
          <list-item>
            <p>Facial porokeratosis</p>
          </list-item>
          <list-item>
            <p>Giant porokeratosis</p>
          </list-item>
          <list-item>
            <p>Porokeratosis ptychotropica</p>
          </list-item>
          <list-item>
            <p>Hypertrophic verrucous porokeratosis</p>
          </list-item>
          <list-item>
            <p>Eruptive pruritic papular porokeratosis</p>
          </list-item>
          <list-item>
            <p>Follicular porokeratosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reticulate porokeratosis <xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Variants can occur together&#x000a0;but rarely do.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref><xref ref-type="bibr" rid="article-27438.r4">[4]</xref><xref ref-type="bibr" rid="article-27438.r5">[5]</xref>&#x000a0;Porokeratosis is a precancerous lesion that can undergo malignant transformation.<xref ref-type="bibr" rid="article-27438.r6">[6]</xref>&#x000a0;Evaluation of porokeratosis is best conducted with a biopsy of the elevated border.&#x000a0;Although multiple therapies exist for porokeratosis&#x000a0;(including topical, systemic, and surgical), there are no standard guidelines for treatment.<xref ref-type="bibr" rid="article-27438.r7">[7]</xref></p>
      </sec>
      <sec id="article-27438.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Despite being first described over a century ago, the etiology and pathology of porokeratosis are unclear, complex, and multifactorial.<xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;Suggested etiologies include ultraviolet (UV) light, repeated frictional trauma, genetics, infectious agents, malignancy, and immunosuppression (ie. transplant patients).<xref ref-type="bibr" rid="article-27438.r8">[8]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r9">[9]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r10">[10]</xref>&#x000a0;There are six clinical variants of porokeratosis: disseminated superficial porokeratosis (DSP), disseminated superficial actinic porokeratosis (DSAP), eruptive disseminated porokeratosis (EDP), porokeratosis of Mibelli, linear porokeratosis, and punctate palmoplantar porokeratosis.<xref ref-type="bibr" rid="article-27438.r10">[10]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r11">[11]</xref>.&#x000a0;Disseminated superficial actinic porokeratosis, the most common variant of porokeratosis, has an autosomal dominant inheritance pattern with incomplete penetrance.<xref ref-type="bibr" rid="article-27438.r12">[12]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r12">[12]</xref>&#x000a0;Furthermore, a mutation in the mevalonate kinase gene seen in DSAP is responsible for a crucial role in the cholesterol synthesis pathway and UV light protection: a finding that prompted the exploitation of important medications in the treatment of the disease.<xref ref-type="bibr" rid="article-27438.r10">[10]</xref>&#x000a0;There is a known link between the development of porokeratosis and&#x000a0;UV light exposure, and experimental studies have induced the formation of disseminated superficial actinic porokeratosis.<xref ref-type="bibr" rid="article-27438.r13">[13]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r13">[13]</xref>&#x000a0;</p>
        <p>Certain drugs and treatment modalities are also associated with the formation of porokeratosis.<xref ref-type="bibr" rid="article-27438.r14">[14]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r11">[11]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r15">[15]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r16">[16]</xref>. A systematic review identified 26 patients with drug-induced porokeratosis and found the most common therapies leading to porokeratosis formation are biologic use, phototherapy, and radiotherapy.<xref ref-type="bibr" rid="article-27438.r11">[11]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r11">[11]</xref></p>
        <p>Porokeratosis of Mibelli and disseminated superficial porokeratosis are often associated with systemic immunosuppression therapy, and the prevalence of porokeratosis in organ transplant patients on systemic immunosuppression therapy is 10.68%, according to one study.<xref ref-type="bibr" rid="article-27438.r3">[3]</xref><xref ref-type="bibr" rid="article-27438.r17">[17]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r17">[17]</xref></p>
        <p>Among case reports in the literature, there is inconsistency regarding the timing of onset of porokeratosis after immunosuppression therapy. Reports detail that these lesions can appear anywhere from 3 weeks to 14 years after the initiation of systemic immunosuppression therapies.<xref ref-type="bibr" rid="article-27438.r18">[18]</xref><xref ref-type="bibr" rid="article-27438.r19">[19]</xref><xref ref-type="bibr" rid="article-27438.r18">[18]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r19">[19]</xref><xref ref-type="bibr" rid="article-27438.r19">[19]</xref></p>
      </sec>
      <sec id="article-27438.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Porokeratosis is an uncommon diagnosis and epidemiology depends heavily on the clinical variant. DSAP occurs on sun-exposed areas, DSP and EDP distribution in generalized, porokeratosis of Mibelli and linear subtypes are present in limbs, while punctate is seen in palms and soles.<xref ref-type="bibr" rid="article-27438.r20">[20]</xref>&#x000a0; It is most commonly in the fifth decade of life but can occur at any age and has similar frequencies in males and females.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref>&#x000a0;Although primarily seen in adults, porokeratosis has also been reported in the literature among young children.<xref ref-type="bibr" rid="article-27438.r21">[21]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r21">[21]</xref>&#x000a0;The increased occurrence of disseminated superficial actinic porokeratosis on sun-exposed skin likely indicates that&#x000a0;UV light is a risk factor.<xref ref-type="bibr" rid="article-27438.r22">[22]</xref></p>
        <p>The eruptive form of porokeratosis correlates with immune suppression, transplantation patients, inflammatory states, and malignancy.<xref ref-type="bibr" rid="article-27438.r4">[4]</xref>&#x000a0;Porokeratosis will progress to nonmelanoma skin cancer in&#x000a0;6.9% to 30% of cases, most frequently squamous cell carcinoma and less frequently basal cell carcinoma.<xref ref-type="bibr" rid="article-27438.r6">[6]</xref>&#x000a0;One study of 281 patients with porokeratosis found risks for malignant transformation in patients with linear porokeratosis to be 19%, porokeratosis plantaris, palmaris, et disseminate at 10%, porokeratosis of Mibelli of any size at 8%, and disseminated superficial actinic porokeratosis at 3%.<xref ref-type="bibr" rid="article-27438.r23">[23]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r20">[20]</xref></p>
        <p>It is important to note that porokeratosis lesions do not immediately become cancerous; the average period before it transforms into a cancerous lesion is about 36 years.<xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;Although&#x000a0;porokeratosis is usually an acquired disease, there is often a familial&#x000a0;predisposition that could signify a hereditary component.<xref ref-type="bibr" rid="article-27438.r5">[5]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r10">[10]</xref></p>
      </sec>
      <sec id="article-27438.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Porokeratosis is an entity that&#x000a0;results from the disordered progression of epidermal cells.<xref ref-type="bibr" rid="article-27438.r24">[24]</xref>&#x000a0;The development of this entity&#x000a0;can be related to sun exposure. In areas with no or limited sun exposure, repeated minor frictional trauma due to tight clothing may cause the entity,&#x000a0;as in genitourinary porokeratosis.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;</p>
        <p>There is a reported association with overexpression of p53,&#x000a0;and occasionally, there can be an expansion of a clone of abnormal epidermal keratinocytes.<xref ref-type="bibr" rid="article-27438.r5">[5]</xref><xref ref-type="bibr" rid="article-27438.r6">[6]</xref>&#x000a0;Porokeratosis&#x000a0;has the possibility of malignant transformation into squamous cell carcinoma or basal cell carcinoma.<xref ref-type="bibr" rid="article-27438.r5">[5]</xref></p>
      </sec>
      <sec id="article-27438.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The distinctive histopathologic feature of porokeratosis is a cornoid lamella, a column of tightly fitted parakeratotic cells.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref><xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;The column of parakeratosis will occur over the epidermis with an absent granular layer and dyskeratotic cells in the upper spinous zone.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;This feature is usually present at the elevated border of the lesion.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Although it was&#x000a0;once thought pathognomonic of porokeratosis,&#x000a0;the feature has&#x000a0;presented in other conditions.<xref ref-type="bibr" rid="article-27438.r24">[24]</xref>&#x000a0;Cornoid lamellation reflects a disordered progression of epidermal cells.<xref ref-type="bibr" rid="article-27438.r24">[24]</xref>&#x000a0;In follicular porokeratosis, the cornoid lamella can involve the follicular infundibulum.<xref ref-type="bibr" rid="article-27438.r25">[25]</xref></p>
      </sec>
      <sec id="article-27438.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Porokeratosis presents as keratotic papules or annular plaques that expand centrifugally with an elevated keratotic border.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Centrally, the lesion can appear slightly atrophic.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;The lesions can present with pruritus and may be present for several years before diagnosis.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Disseminated nodules present as pink to brown papules and macules with raised borders.<xref ref-type="bibr" rid="article-27438.r4">[4]</xref>&#x000a0;</p>
        <p>Porokeratosis&#x000a0;most commonly occurs in the limbs and trunk but can occur in the trunk, face, genitourinary region, and scrotum.<xref ref-type="bibr" rid="article-27438.r25">[25]</xref>&#x000a0;However, porokeratosis as an entity has a broad spectrum of presentations, including large destructive lesions and the involvement of burn scars.<xref ref-type="bibr" rid="article-27438.r6">[6]</xref>&#x000a0;Careful attention must be paid to relatively large porokeratosis lesions, located on sun-exposed areas on the extremities, and lesions that have a long duration since onset, as these are all risk factors for malignant transformation.<xref ref-type="bibr" rid="article-27438.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27438.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of porokeratosis is best with a biopsy of the elevated border.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Biopsy in this area will show the cornoid lamella and will be diagnostic. Dermoscopy can also be helpful for diagnosis. Dermoscopy of lesions shows central brown pigmentation with blue-gray dots surrounded by a single hypopigmented band with a white track at the periphery.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Despite the relative rarity of porokeratosis, especially some subtypes like genitourinary porokeratosis, the diagnosis should be kept in mind due to the risk of malignant degeneration.<xref ref-type="bibr" rid="article-27438.r6">[6]</xref></p>
      </sec>
      <sec id="article-27438.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Multiple therapies&#x000a0;have been described for the different clinical variations of porokeratosis, including topical, systemic, and surgical options. However, because porokeratosis has not been studied in randomized controlled trials, there are no international guidelines on treatment standards.<xref ref-type="bibr" rid="article-27438.r7">[7]</xref>&#x000a0;Various forms of&#x000a0;porokeratosis have been effectively treated as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Classical porokeratosis of Mibelli:</bold>&#x000a0;Most successfully treated with imiquimod cream&#x000a0;<xref ref-type="bibr" rid="article-27438.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>DSAP</bold>
<list list-type="bullet"><list-item><p>Diclofenac 3% gel: rated 4/10 efficacy with minimal&#x000a0;adverse&#x000a0;effects.&#x000a0;<xref ref-type="bibr" rid="article-27438.r26">[26]</xref>&#x000a0;<xref ref-type="bibr" rid="article-27438.r27">[27]</xref></p></list-item><list-item><p>Radiotherapy: at least 50% effectiveness, side effects include pigmentation disorders, alopecia, skin atrophy, telangiectasia, fibrosis, and secondary skin malignancies.<xref ref-type="bibr" rid="article-27438.r28">[28]</xref><xref ref-type="bibr" rid="article-27438.r29">[29]</xref><xref ref-type="bibr" rid="article-27438.r30">[30]</xref></p></list-item><list-item><p>Vitamin D3 analogues proven effective: calcipotriol 0.005% twice daily, tacalcitol 0.002% or 0.004%, calcipotriol 0.005% / adapalene 0.1% gel, calcipotriol/ betamethasone gel, and CO2 laser with tacalcitol 0.002% ointment.<xref ref-type="bibr" rid="article-27438.r20">[20]</xref></p></list-item><list-item><p>Laser therapy and cryotherapy have shown excellent results.&#x000a0;<xref ref-type="bibr" rid="article-27438.r20">[20]</xref></p></list-item><list-item><p>Topical 2% levostatin: a 2023 randomized controlled trial showed excellent results and suggested levostatin cream as a primary treatment option.<xref ref-type="bibr" rid="article-27438.r31">[31]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Linear porokeratosis:</bold>&#x000a0;Responds well to topical or systemic retinoids&#x000a0;<xref ref-type="bibr" rid="article-27438.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>DSP:</bold> treatment is similar to DSAP with the exclusion of topical statin. Small reports have also studied the efficacy of dimethyl sulphoxide (DMSO)<xref ref-type="bibr" rid="article-27438.r32">[32]</xref>, oral tofacitinib<xref ref-type="bibr" rid="article-27438.r33">[33]</xref>, and a traditional Chinese herbal medicine called Huang-Lian-Jie-Tang.<xref ref-type="bibr" rid="article-27438.r34">[34]</xref> All these medications were proven to provide relief of pruritis in small sample-size studies.</p>
          </list-item>
          <list-item>
            <p><bold>Eruptive Disseminated porokeratosis (EDP):</bold>&#x000a0;a subvariant of DSP, tends to subside spontaneously within a month.&#x000a0;<xref ref-type="bibr" rid="article-27438.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Punctate porokeratosis:</bold> data on treatment is scarce, but systemic retinoids such as isotretinoin, etrenitate, and acitretin are the medications with the best-documented effect.<xref ref-type="bibr" rid="article-27438.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Surgical interventions, such as sharp excision, curettage and electrodesiccation are options for treatment in areas where topical agents are challenging to use or contraindicated.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK532290/">[7]</ext-link>&#x000a0;</p>
        <p>In general, patients with a few, small lesions who would like a quick resolution and can tolerate the potential for potential aesthetic complications are good candidates for surgical or laser modalities. Patients with multiple, large lesions are not good surgical candidates and would be best managed by topical pharmacologic therapies. Lastly, patients who are hesitant to pursue surgical or intensive topical pharmacologic therapy are best managed by topical keratolytic agents.</p>
      </sec>
      <sec id="article-27438.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Clinically, porokeratosis can resemble:</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Lichen simplex&#x000a0;chronicus</p>
          </list-item>
          <list-item>
            <p>Hypertrophic lichen planus</p>
          </list-item>
          <list-item>
            <p>Tuberculosis of the skin</p>
          </list-item>
          <list-item>
            <p>Bowen disease</p>
          </list-item>
          <list-item>
            <p>Candidiasis</p>
          </list-item>
          <list-item>
            <p>Irritants</p>
          </list-item>
          <list-item>
            <p>Allergic contact dermatitis <xref ref-type="bibr" rid="article-27438.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27438.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Porokeratosis will remain indefinitely without medical or surgical intervention, and spontaneous regression of these lesions is extremely rare.<xref ref-type="bibr" rid="article-27438.r18">[18]</xref>&#x000a0;Porokeratosis is a premalignant condition<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>; however, all types of porokeratosis can undergo malignant transformation to nonmelanoma skin cancer&#x000a0;at a rate of 6.9% to 30%.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref><xref ref-type="bibr" rid="article-27438.r6">[6]</xref>&#x000a0;Most commonly, porokeratosis lesions transform into squamous cell carcinoma; less frequently, they transform into basal cell carcinoma. If the lesions&#x000a0;have not undergone a malignant transformation, excision is curative.</p>
        <p>Linear porokeratosis and giant porokeratosis are the variants that are most susceptible to malignant transformation. Malignant transformation is rare in disseminated superficial actinic porokeratosis.<xref ref-type="bibr" rid="article-27438.r36">[36]</xref></p>
      </sec>
      <sec id="article-27438.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of porokeratosis are based on treatment selection. General complications of surgical excision include infection, bleeding, and scarring. Topical treatments can irritate the skin or cause skin atrophy, pruritus, xerosis, or pigmentation changes. Complications can also be related to a lack of early diagnosis with a biopsy and a lack of treatment, leading to the potential for malignant transformation.&#x000a0;</p>
      </sec>
      <sec id="article-27438.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with&#x000a0;porokeratosis may consult with the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dermatologists</p>
          </list-item>
          <list-item>
            <p>Dermatology nurses</p>
          </list-item>
          <list-item>
            <p>Mohs surgeons</p>
          </list-item>
          <list-item>
            <p>Plastic surgeons</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27438.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Porokeratosis is a precancerous skin lesion that presents with small, callus-like raised lesions (keratotic papules) or flat, round-shaped lesions (annular plaques) with an elevated border. These lesions become cancerous anywhere from 6.9% to 30% of the time, based on current research, and most frequently transform into squamous cell carcinoma.</p>
        <p>Porokeratosis is often found in sun-exposed areas and is noted in the fifth decade of life. Interestingly, several different clinical variants of porokeratosis exist, but the exact etiology and pathology of these lesions remain unclear. Of all the clinical variants, linear and giant porokeratosis have the worst prognosis, as they are most likely to undergo malignant transformation. On the other hand, malignant transformation is rare in disseminated superficial actinic porokeratosis. There may be a multifactorial cause of Porokeratosis with possible etiologies, including&#x000a0;UV light, trauma, genetics, infectious agents, and immunosuppression.</p>
        <p>In addition to clinical evaluation, the best method for definitive diagnosis is a biopsy of the elevated border. Biopsy in this area will show the cornoid lamella and will be diagnostic.&#x000a0;Clinically, porokeratosis can resemble other skin conditions, such as&#x000a0;psoriasis, lichen simplex&#x000a0;chronicus, hypertrophic lichen planus, tuberculosis of the skin, Bowen disease, candidiasis, irritants,&#x000a0;and allergic contact dermatitis.</p>
        <p>Multiple therapies are&#x000a0;described for porokeratosis, including topical, systemic, and surgical options. Patients should be evaluated annually to monitor for signs and symptoms of malignancy to reduce the risk of malignant transformation of porokeratosis. In addition, providers will screen for underlying systemic immunosuppressive disorders and re-educate sun protection.</p>
        <p>If the lesions carry several risk factors for malignant transformation, such as large, numerous, and long-standing lesions, bi-annual follow-up visits should be scheduled. If a porokeratosis lesion begins to exhibit clinical features concerning for a malignancy, a patient sees a provider immediately for excision or biopsy.</p>
      </sec>
      <sec id="article-27438.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Histologically, the hallmark of porokeratosis is a cornoid lamella, a column of tightly fitted parakeratotic cells.<xref ref-type="bibr" rid="article-27438.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Porokeratosis&#x000a0;presents as keratotic papules or annular plaques that expand centrifugally with an elevated keratotic border.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref>&#x000a0;Dermoscopy&#x000a0;of lesions shows central brown pigmentation with blue-gray dots surrounded by a single hypopigmented band with a white track at the periphery.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>There are many variants of porokeratosis.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Porokeratosis can undergo malignant transformation to squamous cell carcinoma and basal cell carcinoma.<xref ref-type="bibr" rid="article-27438.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Evaluation of porokeratosis is best done with a biopsy of the elevated border.<xref ref-type="bibr" rid="article-27438.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Multiple therapies are&#x000a0;described&#x000a0;for porokeratosis, including topical, systemic, and surgical options. However, because porokeratosis has not been studied in randomized controlled trials, there are no international guidelines on treatment standards.<xref ref-type="bibr" rid="article-27438.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Patients treated for porokeratosis should&#x000a0;be advised&#x000a0;to use sun protection, avoid excessive sunlight exposure, and undergo periodic examinations by a dermatologist to monitor for recurrence or malignant transformation.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27438.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dermatologists and other clinicians should work closely with pathologists to ensure porokeratosis lesions are evaluated for malignant transformation.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref>&#x000a0;Dermatologists and dermatology specialty nurses should periodically follow up&#x000a0;with patients to monitor for recurrence.<xref ref-type="bibr" rid="article-27438.r2">[2]</xref>&#x000a0;An interprofessional team approach to follow-up will provide the best patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-27438.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27438&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27438">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/porokeratosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27438">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27438/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27438">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27438.s18">
        <fig id="article-27438.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Disseminated Superficial Actinic Porokeratosis (DSAP) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dsap" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27438.s19">
        <fig id="article-27438.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Porokeratosis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="porokeratosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27438.s20">
        <fig id="article-27438.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Porokeratosis of Mibelli Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="porokeratosis__of__MibelliSV" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27438.s21">
        <title>References</title>
        <ref id="article-27438.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Minni</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Genitogluteal porokeratosis: a clinical review.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>219</fpage>
            <page-range>219-229</page-range>
            <pub-id pub-id-type="pmid">29750048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leow</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Soon</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>A report of 31 cases of porokeratosis at the National Skin Centre.</article-title>
            <source>Ann Acad Med Singap</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>837</fpage>
            <page-range>837-41</page-range>
            <pub-id pub-id-type="pmid">9055013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sertznig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>von Felbert</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Megahed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Porokeratosis: present concepts.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>404</fpage>
            <page-range>404-12</page-range>
            <pub-id pub-id-type="pmid">21929548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Le</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bedocs</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <chapter-title>Disseminated Superficial Actinic Porokeratosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">29083728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanitakis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features.</article-title>
            <source>Eur J Dermatol</source>
            <year>2014</year>
            <season>Sep-Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>533</fpage>
            <page-range>533-44</page-range>
            <pub-id pub-id-type="pmid">25115203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hivnor</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A case of genital porokeratosis and review of literature.</article-title>
            <source>Indian J Dermatol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <pub-id pub-id-type="pmid">25814761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weidner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Illing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Porokeratosis: A Systematic Review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>435</fpage>
            <page-range>435-449</page-range>
            <pub-id pub-id-type="pmid">28283894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZZ</given-names>
              </name>
            </person-group>
            <article-title>Clinical analysis and etiology of porokeratosis.</article-title>
            <source>Exp Ther Med</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>737</fpage>
            <page-range>737-741</page-range>
            <pub-id pub-id-type="pmid">25120591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargas-Mora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morgado-Carrasco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fust&#x000e0;-Novell</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Porokeratosis: A Review of Its Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment.</article-title>
            <source>Actas Dermosifiliogr (Engl Ed)</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>545</fpage>
            <page-range>545-560</page-range>
            <pub-id pub-id-type="pmid">32401728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2023</year>
            <month>Oct</month>
            <day>01</day>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1053</fpage>
            <page-range>1053-1057</page-range>
            <pub-id pub-id-type="pmid">37801522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mufti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rahat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lansang</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drugs associated with development of porokeratosis: A systematic review.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>e14560</fpage>
            <pub-id pub-id-type="pmid">33210788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murase</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gilliam</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>886</fpage>
            <page-range>886-91</page-range>
            <pub-id pub-id-type="pmid">20451293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gwak</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Disseminated Superficial Actinic Porokeratosis in a Vitiligo Patient Undergoing Treatment with Long-Term Narrowband Ultraviolet B.</article-title>
            <source>Ann Dermatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-251</page-range>
            <pub-id pub-id-type="pmid">29606833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campainha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>C&#x000e9;sar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histopathologic findings of drug-induced eruptive porokeratosis under nivolumab therapy.</article-title>
            <source>J Cutan Pathol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-300</page-range>
            <pub-id pub-id-type="pmid">36515632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frew</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Parsi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Adalimumab-induced porokeratosis.</article-title>
            <source>Australas J Dermatol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>e80</fpage>
            <page-range>e80-1</page-range>
            <pub-id pub-id-type="pmid">26201378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Gru</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hamann</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Temozolomide-induced inflammation of disseminated superficial actinic porokeratosis.</article-title>
            <source>Dermatol Online J</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>24</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29634886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herranz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pizarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Lucas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robayna</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Contreras</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casado</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>High incidence of porokeratosis in renal transplant recipients.</article-title>
            <source>Br J Dermatol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-9</page-range>
            <pub-id pub-id-type="pmid">9068727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanitakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Euvrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Claudy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Porokeratosis and immunosuppression.</article-title>
            <source>Eur J Dermatol</source>
            <year>1998</year>
            <season>Oct-Nov</season>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>459</fpage>
            <page-range>459-65</page-range>
            <pub-id pub-id-type="pmid">9854155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bednarek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ezra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Toubin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Linos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mousdicas</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>753</fpage>
            <page-range>753-6</page-range>
            <pub-id pub-id-type="pmid">25800103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pietkiewicz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korecka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Salwowska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kohut</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Adhikari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bowszyc-Dmochowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pogorzelska-Antkowiak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarrete-Dechent</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Porokeratoses-A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants.</article-title>
            <source>Metabolites</source>
            <year>2023</year>
            <month>Nov</month>
            <day>26</day>
            <volume>13</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">38132857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niimi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawana</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl.</article-title>
            <source>Eur J Dermatol</source>
            <year>2009</year>
            <season>Jan-Feb</season>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-8</page-range>
            <pub-id pub-id-type="pmid">19059828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumann</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Jurecka</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gebhart</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>1182</fpage>
            <page-range>1182-8</page-range>
            <pub-id pub-id-type="pmid">2584454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krain</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Porokeratosis and cutaneous malignancy. A review.</article-title>
            <source>Dermatol Surg</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-42</page-range>
            <pub-id pub-id-type="pmid">8624658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wade</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Cornoid lamellation. A histologic reaction pattern.</article-title>
            <source>Am J Dermatopathol</source>
            <year>1980</year>
            <season>Spring</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-15</page-range>
            <pub-id pub-id-type="pmid">7246969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanusi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Porokeratosis with follicular involvement: report of three cases and review of literatures.</article-title>
            <source>Int J Clin Exp Pathol</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>4248</fpage>
            <page-range>4248-52</page-range>
            <pub-id pub-id-type="pmid">26097620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muellenhoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-5</page-range>
            <pub-id pub-id-type="pmid">18702625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darr-Foit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elsner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[77-year-old female with persisting erythematous and scaly plaques on the extremities and upper trunk : Preparation for the medical specialist examination: Part&#x000a0;20].</article-title>
            <source>Hautarzt</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>Suppl 2</issue>
            <fpage>165</fpage>
            <page-range>165-168</page-range>
            <pub-id pub-id-type="pmid">30374539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramelyte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bylaite-Bucinskiene</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Imhof</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases.</article-title>
            <source>Dermatology</source>
            <year>2017</year>
            <volume>233</volume>
            <issue>2-3</issue>
            <fpage>217</fpage>
            <page-range>217-222</page-range>
            <pub-id pub-id-type="pmid">28817832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ting</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Grenz ray therapy in disseminated superficial actinic porokeratosis: A case series of 17 patients.</article-title>
            <source>Australas J Dermatol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-94</page-range>
            <pub-id pub-id-type="pmid">34905626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spelman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaminski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Supranowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy, Utilizing Volumetric Modulated Arc Therapy, for Extensive Skin Field Cancerization: A Retrospective Case Series Assessing Efficacy, Safety, and Cosmetic Outcomes at 12 Months After Treatment.</article-title>
            <source>Case Rep Dermatol</source>
            <year>2022</year>
            <season>Jan-Apr</season>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-38</page-range>
            <pub-id pub-id-type="pmid">35431855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santa Lucia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lateef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drohan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gregoski</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis: A Randomized Clinical Trial.</article-title>
            <source>JAMA Dermatol</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>159</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-495</page-range>
            <pub-id pub-id-type="pmid">36947042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahramiyanpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Heiran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alipour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parvizi</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: A split-side single-blinded randomized clinical trial.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>e13305</fpage>
            <pub-id pub-id-type="pmid">32160368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Eruptive Pruritic Papular Porokeratosis in the Elderly with Tofacitinib: A Case Report.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>1741</fpage>
            <page-range>1741-1747</page-range>
            <pub-id pub-id-type="pmid">37435395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ariizumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kadono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyagaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Complete pruritus relief by oren-gedoku-to in eruptive pruritic papular porokeratosis.</article-title>
            <source>J Dermatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>e378</fpage>
            <page-range>e378-e379</page-range>
            <pub-id pub-id-type="pmid">33982823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Eruptive pruritic papular porokeratosis.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-169</page-range>
            <pub-id pub-id-type="pmid">34408586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27438.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Fatal squamous cell carcinoma arising from transplant-associated porokeratosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>931</fpage>
            <page-range>931-3</page-range>
            <pub-id pub-id-type="pmid">14576684</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
